eCQM Title

Initiation and Engagement of Substance Use Disorder Treatment

eCQM Identifier (Measure Authoring Tool)

137

eCQM Version Number

13.0.000

CBE Number

Not Applicable

GUID

c3657d72-21b4-4675-820a-86c7fe293bf5

Measurement Period

January 1, 20XX through December 31, 20XX

Measure Steward

National Committee for Quality Assurance

Measure Developer

National Committee for Quality Assurance

Endorsed By

None

Description

Percentage of patients 13 years of age and older with a new substance use disorder (SUD) episode who received the following (Two rates are reported):

a. Percentage of patients who initiated treatment, including either an intervention or medication for the treatment of SUD, within 14 days of the new SUD episode. 
b. Percentage of patients who engaged in ongoing treatment, including two additional interventions or medication treatment events for SUD, or one long-acting medication event for the treatment of SUD, within 34 days of the initiation.

This Physician Performance Measure (Measure) and related data specifications are owned and were developed by the National Committee for Quality Assurance (NCQA). NCQA is not responsible for any use of the Measure. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in the Measure. The Measure can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by healthcare providers in connection with their practices) without obtaining approval from NCQA. Commercial use is defined as the sale, licensing, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses or requests for modification must be approved by NCQA and are subject to a license at the discretion of NCQA. (C) 2012-2024 National Committee for Quality Assurance. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any third-party codes contained in the specifications.

CPT(R) codes, descriptions and other data are copyright 2024. American Medical Association. All rights reserved. CPT is a trademark of the American Medical Association. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Applicable FARS/DFARS restrictions apply to government use.

Some measure specifications contain coding from LOINC(R) (http://loinc.org). The LOINC table, LOINC codes, LOINC panels and form file, LOINC linguistic variants file, LOINC/RSNA Radiology Playbook, and LOINC/IEEE Medical Device Code Mapping Table are copyright 2004-2024 Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee, and are available at no cost under the license at http://loinc.org/terms-of-use.

Some measures use RxNorm, a standardized nomenclature and coding for clinical drugs and drug delivery devices, which is made publicly available courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services. NLM is not responsible for the measures and does not endorse or recommend this or any other product.

“HL7” is the registered trademark of Health Level Seven International.

Disclaimer

The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
 
Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].

Measure Scoring

Proportion

Measure Type

Process

Stratification

Report a total score, and each of the following strata:
Stratum 1: Patients age 13-17 at the start of the measurement period
Stratum 2: Patients age 18-64 at the start of the measurement period
Stratum 3: Patients age 65 and older at the start of the measurement period

Risk Adjustment

None

Rate Aggregation

None

Rationale

There are more deaths, illnesses and disabilities from substance abuse than from any other preventable health condition. In 2021, 46.3 million individuals in the U.S. age 12 or older (16.5 percent of the population) met the diagnosis criteria for having an SUD within the past year (Substance Abuse and Mental Health Services Administration [SAMHSA], 2022). Despite the high prevalence of SUD in the U.S., 94 percent of individuals aged 12 or older with an SUD did not receive any treatment (SAMHSA, 2022).

Clinical Recommendation Statement

American Society of Addiction Medicine (2020)
- All Food and Drug Administration approved medications for the treatment of opioid use disorder should be available to all patients. Clinicians should consider the patient’s preferences, past treatment history, current state of illness, and treatment setting when deciding between the use of methadone, buprenorphine, and naltrexone.
- There is no recommended time limit for pharmacological treatment
- Patients’ psychosocial needs should be assessed, and patients should be offered or referred to psychosocial treatment based on their individual needs. However, a patient’s decision to decline psychosocial treatment or the absence of available psychosocial treatment should not preclude or delay pharmacotherapy, with appropriate medication management. Motivational interviewing or enhancement can be used to encourage patients to engage in psychosocial treatment services appropriate for addressing individual needs.

American Psychiatric Association (2018)
- Patients with alcohol use disorder should have a documented comprehensive and person-centered treatment plan that includes evidence-based nonpharmacological and pharmacological treatments. [1C]
- Naltrexone or acamprosate should be offered to patients with moderate to severe alcohol use disorder who have a goal of reducing alcohol consumption or achieving abstinence, prefer pharmacotherapy or have not responded to nonpharmacological treatments alone, and have no contraindications to the use of these medications. [1B]
- Disulfiram should be offered to patients with moderate to severe alcohol use disorder who have a goal of achieving abstinence, prefer disulfiram or are intolerant to or have not responded to naltrexone and acamprosate, are capable of understanding the risks of alcohol consumption while taking disulfiram, and have no contraindications to the use of this medication. [2C]
- Topiramate or gabapentin should be offered to patients with moderate to severe alcohol use disorder who have a goal of reducing alcohol consumption or achieving abstinence, prefer topiramate or gabapentin or are intolerant to or have not responded to naltrexone and acamprosate, and have no contraindications to the use of these medications. [2C]

American Psychiatric Association (2006)
- Because many substance use disorders are chronic, patients usually require long-term treatment, although the intensity and specific components of treatment may vary over time [I rating].
- It is important to intensify the monitoring for substance use during periods when the patient is at a high risk of relapsing, including during the early stages of treatment, times of transition to less intensive levels of care, and the first year after active treatment has ceased [I rating].
- Outpatient treatment of substance use disorders is appropriate for patients whose clinical condition or environmental circumstances do not require a more intensive level of care [I rating]. As in other treatment settings, a comprehensive approach is optimal, using, where indicated, a variety of psychotherapeutic and pharmacological interventions along with behavioral monitoring [I rating].
- Disulfiram is also recommended for patients with alcohol dependence [II rating].
- Naltrexone, injectable naltrexone, acamprosate, a y-aminobutyric acid (GABA) are recommended for patients with alcohol dependence [I rating]. Disulfiram is also recommended for patients with alcohol dependence [II rating].
- Methadone and buprenorphine are recommended for patients with opioid dependence [I rating].
- Naltrexone is an alternative strategy [I rating].

American Society of Addiction Medicine (2015)
- Methadone and buprenorphine are recommended for opioid use disorder treatment and withdrawal management.
- Naltrexone (oral; extended-release injectable) is recommended for relapse prevention.

Michigan Quality Improvement Consortium (2021)
- Patients with substance use disorder or risky substance use: Patient Education and Brief Intervention by a Primary Care Physician (PCP) or Trained Staff (e.g., Registered Nurse [RN], Master of Social Work [MSW])
- If diagnosed with substance use disorder or risky substance use, initiate an intervention within 14 days.
- Frequent follow-up is helpful to support behavior change; preferably 2 visits within 30 days.
- Refer to a substance abuse health specialist, an addiction physician specialist, or a physician experienced in pharmacologic management of addiction.

Department of Veterans Affairs/Department of Defense (2015)
- Offer referral to specialty SUD care for addiction treatment based on willingness to engage. [B]
- For patients with moderate-severe alcohol use disorder, we recommend: Acamprosate, Disulfiram, Naltrexone- oral or extended release, or Topiramate. [A]
- Medications should be offered in combined with addiction-focused counseling, offering one or more of the following interventions considering patient preference and provider training/competence: Behavioral Couples Therapy for alcohol use disorder, Cognitive Behavioral Therapy for substance use disorders, Community Reinforcement Approach, Motivational Enhancement Therapy, 12-Step Facilitation. [A]
- For patients with opioid use disorder we recommend buprenorphine/naloxone or methadone in an Opioid Treatment Program. For patients for whom agonist treatment is contraindicated, unacceptable, unavailable, or discontinued, we recommend extended-release injectable naltrexone. [A]
- For patients initiated in an intensive phase of outpatient or residential treatment, recommend ongoing systematic relapse prevention efforts or recovery support, individualized on the basis of treatment response. [A]

Improvement Notation

Higher score indicates better quality

Reference

Reference Type: CITATION

Reference Text: 'American Psychiatric Association, Kleber, H. D., & McIntyre, J. S. (2006). Practice Guideline for Treatment of Patients with Substance Use Disorders (pp. 1-276). Arlington, VA: American Psychiatric Association.'

Reference

Reference Type: CITATION

Reference Text: 'American Society of Addiction Medicine (ASAM). (2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.'

Reference

Reference Type: CITATION

Reference Text: 'Department of Veteran Affairs, Department of Defense. (2015). VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington DC: Department of Veterans Affairs, Department of Defense.'

Reference

Reference Type: CITATION

Reference Text: 'Kampman, K., Jarvis, M. (2015). The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of Addiction Medicine; 9(5), 358–367. https://doi.org/10.1097/ADM.0000000000000166'

Reference

Reference Type: CITATION

Reference Text: 'Michigan Quality Improvement Consortium. (2021). Screening, Diagnosis and Referral for Substance Use Disorders. Southfield, (MI): Michigan Quality Improvement Consortium. Retrieved from https://www.improve.health/wp-content/uploads/2023/04/mqicscreeningdiagnosisandreferralforsubstanceusedisordersFINAL-1.pdf'

Reference

Reference Type: CITATION

Reference Text: 'Reus, V. et al. (2018). Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder. American Journal of Psychiatry, 175(1), 86-90. https://doi.org/10.1176/appi.ajp.2017.1750101'

Reference

Reference Type: CITATION

Reference Text: 'Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report'

Definition

The new SUD episode is the first encounter during the Intake Period with a diagnosis of SUD with no encounter or medication treatment for a diagnosis of SUD in the 60 days prior.

The initiation of treatment is the first SUD treatment within 14 days of a new SUD episode.

Treatment includes inpatient SUD admissions, outpatient visits, intensive outpatient encounters or partial hospitalizations, and medications for the treatment of SUD.

The Intake Period: January 1-November 14 of the measurement year. The Intake Period is used to capture new SUD episodes. The November 14 cut-off date ensures that all services can occur before the measurement period ends.

Guidance

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.6. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

Transmission Format

TBD

Initial Population

Patients 13 years of age and older as of the start of the measurement period who were diagnosed with a new SUD episode during a visit between January 1 and November 14 of the measurement period

Denominator

Equals Initial Population

Denominator Exclusions

Exclude patients who are in hospice care for any part of the measurement period

Numerator

Numerator 1: Initiation of treatment includes either an intervention or medication for the treatment of SUD within 14 days of the new SUD episode.

Numerator 2: Engagement in ongoing SUD treatment within 34 days of initiation includes:

1. A long-acting SUD medication on the day after the initiation through 34 days after the initiation of treatment.

2. One of the following options on the day after the initiation of treatment through 34 days after the initiation of treatment: a) two engagement visits, b) two engagement medication treatment events, c) one engagement visit and one engagement medication treatment event.

Numerator Exclusions

Not Applicable

Denominator Exceptions

None

Supplemental Data Elements

For every patient evaluated by this measure also identify payer, race, ethnicity and sex

Population Criteria
Definitions
Functions
Terminology
Data Criteria (QDM Data Elements)
Supplemental Data Elements
Risk Adjustment Variables

Population Criteria

Definitions

Denominator
- - "Initial Population"

Denominator Exclusions
- - Hospice."Has Hospice Services"

Emergency Department or Detoxification Visit

["Encounter, Performed": "Emergency Department Evaluation and Management Visit"]
  union ["Encounter, Performed": "Detoxification Visit"]

First SUD Episode During Measurement Period

First(("Qualifying Encounters") ValidEncounters
    with ["Diagnosis": "Substance Use Disorder"] SUDDiagnosis
      such that ValidEncounters.relevantPeriod during "Measurement Period"
        and SUDDiagnosis.prevalencePeriod starts during ValidEncounters.relevantPeriod
        and SUDDiagnosis.prevalencePeriod starts 47 days or more before day of 
        end of "Measurement Period"
    sort by start of relevantPeriod
)

Has Treatment Engagement With Long Acting Medication

exists ( ( ["Medication, Order": "Substance Use Disorder Long Acting Medication"] LongActingMedOrder
      with ( Min("Treatment Initiation With Non Medication Intervention Dates"
          union "Treatment Initiation With Medication Order Dates"
      ) ) InitiationTreatmentDate
        such that date from LongActingMedOrder.authorDatetime 34 days or less after InitiationTreatmentDate
  )
    union ( ["Procedure, Performed": "Substance Use Disorder Long Acting Medication Administration"] LongActingTreatment
        with ( Min("Treatment Initiation With Non Medication Intervention Dates"
            union "Treatment Initiation With Medication Order Dates"
        ) ) InitiationTreatmentDate
          such that date from start of Global."NormalizeInterval" ( LongActingTreatment.relevantDatetime, LongActingTreatment.relevantPeriod ) 34 days or less after InitiationTreatmentDate
    )
)

Has Two or More Treatment Engagements With Short Acting Medication or Non Medication Intervention

Count((("Psychosocial Visit"
      union ["Procedure, Performed": "Substance Use Disorder Short Acting Medication Administration"]) ShortActingTreatment
      with(Min("Treatment Initiation With Non Medication Intervention Dates"
          union "Treatment Initiation With Medication Order Dates"
      )) InitiationTreatmentDate
        such that date from start of Global."NormalizeInterval"(ShortActingTreatment.relevantDatetime, ShortActingTreatment.relevantPeriod) 34 days or less after InitiationTreatmentDate
      return all ShortActingTreatment
  )
    union(["Medication, Order": "Substance Use Disorder Short Acting Medication"] ShortActingMedOrder
        with(Min("Treatment Initiation With Non Medication Intervention Dates"
            union "Treatment Initiation With Medication Order Dates"
        )) InitiationTreatmentDate
          such that date from ShortActingMedOrder.authorDatetime 34 days or less after InitiationTreatmentDate
        return all ShortActingMedOrder
    )
) >= 2

History of SUD Diagnosis or Treatment

( ( ["Intervention, Performed": "Substance Use Disorder Treatment"]
    union ["Intervention, Performed": "Psych Visit Psychotherapy"]
    union ["Procedure, Performed": "Substance Use Disorder Long Acting Medication Administration"]
    union ["Procedure, Performed": "Substance Use Disorder Short Acting Medication Administration"] ) Interventions
    with "First SUD Episode During Measurement Period" FirstSUDEpisode
      such that Global."NormalizeInterval" ( Interventions.relevantDatetime, Interventions.relevantPeriod ) starts 60 days or less before day of start of FirstSUDEpisode.relevantPeriod
)
  union ( ( ( "Qualifying Encounters"
      except "Emergency Department or Detoxification Visit" ) QualifyingEncounter
      where ( exists QualifyingEncounter.diagnoses Diagnosis
          where Diagnosis.code in "Substance Use Disorder"
      ) ) EncounterWithDiagnosis
      with "First SUD Episode During Measurement Period" FirstSUDEpisode
        such that EncounterWithDiagnosis.relevantPeriod starts 60 days or less before day of start of FirstSUDEpisode.relevantPeriod
  )
  union ( ( ["Medication, Order": "Substance Use Disorder Long Acting Medication"]
      union ["Medication, Order": "Substance Use Disorder Short Acting Medication"] ) SUDMedication
      with "First SUD Episode During Measurement Period" FirstSUDEpisode
        such that SUDMedication.authorDatetime 60 days or less before day of start of FirstSUDEpisode.relevantPeriod
  )

Hospice.Has Hospice Services

exists ( ["Encounter, Performed": "Encounter Inpatient"] InpatientEncounter
    where ( InpatientEncounter.dischargeDisposition ~ "Discharge to home for hospice care (procedure)"
        or InpatientEncounter.dischargeDisposition ~ "Discharge to healthcare facility for hospice care (procedure)"
    )
      and InpatientEncounter.relevantPeriod ends during day of "Measurement Period"
)
  or exists ( ["Encounter, Performed": "Hospice Encounter"] HospiceEncounter
      where HospiceEncounter.relevantPeriod overlaps day of "Measurement Period"
  )
  or exists ( ["Assessment, Performed": "Hospice care [Minimum Data Set]"] HospiceAssessment
      where HospiceAssessment.result ~ "Yes (qualifier value)"
        and Global."NormalizeInterval" ( HospiceAssessment.relevantDatetime, HospiceAssessment.relevantPeriod ) overlaps day of "Measurement Period"
  )
  or exists ( ["Intervention, Order": "Hospice Care Ambulatory"] HospiceOrder
      where HospiceOrder.authorDatetime during day of "Measurement Period"
  )
  or exists ( ["Intervention, Performed": "Hospice Care Ambulatory"] HospicePerformed
      where Global."NormalizeInterval" ( HospicePerformed.relevantDatetime, HospicePerformed.relevantPeriod ) overlaps day of "Measurement Period"
  )
or exists ( ["Diagnosis": "Hospice Diagnosis"] HospiceCareDiagnosis
      where HospiceCareDiagnosis.prevalencePeriod overlaps day of "Measurement Period"
  )

Initial Population

AgeInYearsAt(date from start of "Measurement Period") >= 13
  and "First SUD Episode During Measurement Period" is not null
  and not exists "History of SUD Diagnosis or Treatment"

Numerator 1

exists "Treatment Initiation With Non Medication Intervention Dates"
  or exists "Treatment Initiation With Medication Order Dates"

Numerator 2

"Has Treatment Engagement With Long Acting Medication"
  or "Has Two or More Treatment Engagements With Short Acting Medication or Non Medication Intervention"

Psychosocial Visit

["Intervention, Performed": "Substance Use Disorder Treatment"]
  union ["Intervention, Performed": "Psych Visit Psychotherapy"]
  union ( ( ["Encounter, Performed": "Telephone Visits"]
      union ["Encounter, Performed": "Virtual Encounter"] ) TelehealthEncounter
      where exists TelehealthEncounter.diagnoses Diagnosis
        where Diagnosis.code in "Substance Use Disorder"
  )

Qualifying Encounters

( ["Encounter, Performed": "Office Visit"]
    union ["Encounter, Performed": "Emergency Department Evaluation and Management Visit"]
    union ["Encounter, Performed": "Detoxification Visit"]
    union ["Encounter, Performed": "Initial Hospital Inpatient Visit"]
    union ["Encounter, Performed": "Discharge Services Hospital Inpatient Same Day Discharge"]
    union ["Encounter, Performed": "Discharge Services Hospital Inpatient"]
    union ["Encounter, Performed": "Telephone Visits"]
    union ["Encounter, Performed": "Virtual Encounter"]
)

SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

["Patient Characteristic Payer": "Payer Type"]

SDE Race
- - ["Patient Characteristic Race": "Race"]

SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

Stratification 1

AgeInYearsAt(date from start of "Measurement Period") in Interval[13, 17]

Stratification 2

AgeInYearsAt(date from start of "Measurement Period") in Interval[18, 64]

Stratification 3

AgeInYearsAt(date from start of "Measurement Period") >= 65

Treatment Initiation With Medication Order Dates

( ( ["Medication, Order": "Substance Use Disorder Short Acting Medication"]
    union ["Medication, Order": "Substance Use Disorder Long Acting Medication"] ) SUDMedication
    let treatmentDate: date from SUDMedication.authorDatetime
    with "First SUD Episode During Measurement Period" FirstSUDEpisode
      such that treatmentDate during Interval[date from start of FirstSUDEpisode.relevantPeriod, date from start of FirstSUDEpisode.relevantPeriod + 14 days )
    return all treatmentDate
)
  union ( ( ["Procedure, Performed": "Substance Use Disorder Short Acting Medication Administration"]
      union ["Procedure, Performed": "Substance Use Disorder Long Acting Medication Administration"] ) SUDMedAdministration
      let treatmentDate: date from start of Global."NormalizeInterval" ( SUDMedAdministration.relevantDatetime, SUDMedAdministration.relevantPeriod )
      with "First SUD Episode During Measurement Period" FirstSUDEpisode
        such that treatmentDate during Interval[date from start of FirstSUDEpisode.relevantPeriod, date from start of FirstSUDEpisode.relevantPeriod + 14 days )
      return all treatmentDate
  )

Treatment Initiation With Non Medication Intervention Dates

"Psychosocial Visit" PsychosocialVisit
  let treatmentDate: date from start of Global."NormalizeInterval" ( PsychosocialVisit.relevantDatetime, PsychosocialVisit.relevantPeriod )
  with "First SUD Episode During Measurement Period" FirstSUDEpisode
    such that treatmentDate during Interval[date from start of FirstSUDEpisode.relevantPeriod, date from start of FirstSUDEpisode.relevantPeriod + 14 days )
      and PsychosocialVisit.id != FirstSUDEpisode.id
  return all treatmentDate

Functions

Global.NormalizeInterval(pointInTime DateTime, period Interval<DateTime>)

if pointInTime is not null then Interval[pointInTime, pointInTime]
  else if period is not null then period 
  else null as Interval<DateTime>

Terminology

code "Discharge to healthcare facility for hospice care (procedure)" ("SNOMEDCT Code (428371000124100)")
code "Discharge to home for hospice care (procedure)" ("SNOMEDCT Code (428361000124107)")
code "Hospice care [Minimum Data Set]" ("LOINC Code (45755-6)")
code "Yes (qualifier value)" ("SNOMEDCT Code (373066001)")
valueset "Detoxification Visit" (2.16.840.1.113883.3.464.1003.101.12.1059)
valueset "Discharge Services Hospital Inpatient" (2.16.840.1.113883.3.464.1003.101.12.1007)
valueset "Discharge Services Hospital Inpatient Same Day Discharge" (2.16.840.1.113883.3.464.1003.101.12.1006)
valueset "Emergency Department Evaluation and Management Visit" (2.16.840.1.113883.3.464.1003.101.12.1010)
valueset "Encounter Inpatient" (2.16.840.1.113883.3.666.5.307)
valueset "Ethnicity" (2.16.840.1.114222.4.11.837)
valueset "Hospice Care Ambulatory" (2.16.840.1.113883.3.526.3.1584)
valueset "Hospice Diagnosis" (2.16.840.1.113883.3.464.1003.1165)
valueset "Hospice Encounter" (2.16.840.1.113883.3.464.1003.1003)
valueset "Initial Hospital Inpatient Visit" (2.16.840.1.113883.3.464.1003.101.12.1004)
valueset "Office Visit" (2.16.840.1.113883.3.464.1003.101.12.1001)
valueset "ONC Administrative Sex" (2.16.840.1.113762.1.4.1)
valueset "Payer Type" (2.16.840.1.114222.4.11.3591)
valueset "Psych Visit Psychotherapy" (2.16.840.1.113883.3.526.3.1496)
valueset "Race" (2.16.840.1.114222.4.11.836)
valueset "Substance Use Disorder" (2.16.840.1.113883.3.464.1003.106.12.1001)
valueset "Substance Use Disorder Long Acting Medication" (2.16.840.1.113883.3.464.1003.1149)
valueset "Substance Use Disorder Long Acting Medication Administration" (2.16.840.1.113883.3.464.1003.1156)
valueset "Substance Use Disorder Short Acting Medication" (2.16.840.1.113883.3.464.1003.1150)
valueset "Substance Use Disorder Short Acting Medication Administration" (2.16.840.1.113883.3.464.1003.1157)
valueset "Substance Use Disorder Treatment" (2.16.840.1.113883.3.464.1003.106.12.1005)
valueset "Telephone Visits" (2.16.840.1.113883.3.464.1003.101.12.1080)
valueset "Virtual Encounter" (2.16.840.1.113883.3.464.1003.101.12.1089)

Data Criteria (QDM Data Elements)

"Assessment, Performed: Hospice care [Minimum Data Set]" using "Hospice care [Minimum Data Set] (LOINC Code 45755-6)"
"Diagnosis: Hospice Diagnosis" using "Hospice Diagnosis (2.16.840.1.113883.3.464.1003.1165)"
"Diagnosis: Substance Use Disorder" using "Substance Use Disorder (2.16.840.1.113883.3.464.1003.106.12.1001)"
"Encounter, Performed: Detoxification Visit" using "Detoxification Visit (2.16.840.1.113883.3.464.1003.101.12.1059)"
"Encounter, Performed: Discharge Services Hospital Inpatient" using "Discharge Services Hospital Inpatient (2.16.840.1.113883.3.464.1003.101.12.1007)"
"Encounter, Performed: Discharge Services Hospital Inpatient Same Day Discharge" using "Discharge Services Hospital Inpatient Same Day Discharge (2.16.840.1.113883.3.464.1003.101.12.1006)"
"Encounter, Performed: Emergency Department Evaluation and Management Visit" using "Emergency Department Evaluation and Management Visit (2.16.840.1.113883.3.464.1003.101.12.1010)"
"Encounter, Performed: Encounter Inpatient" using "Encounter Inpatient (2.16.840.1.113883.3.666.5.307)"
"Encounter, Performed: Hospice Encounter" using "Hospice Encounter (2.16.840.1.113883.3.464.1003.1003)"
"Encounter, Performed: Initial Hospital Inpatient Visit" using "Initial Hospital Inpatient Visit (2.16.840.1.113883.3.464.1003.101.12.1004)"
"Encounter, Performed: Office Visit" using "Office Visit (2.16.840.1.113883.3.464.1003.101.12.1001)"
"Encounter, Performed: Telephone Visits" using "Telephone Visits (2.16.840.1.113883.3.464.1003.101.12.1080)"
"Encounter, Performed: Virtual Encounter" using "Virtual Encounter (2.16.840.1.113883.3.464.1003.101.12.1089)"
"Intervention, Order: Hospice Care Ambulatory" using "Hospice Care Ambulatory (2.16.840.1.113883.3.526.3.1584)"
"Intervention, Performed: Hospice Care Ambulatory" using "Hospice Care Ambulatory (2.16.840.1.113883.3.526.3.1584)"
"Intervention, Performed: Psych Visit Psychotherapy" using "Psych Visit Psychotherapy (2.16.840.1.113883.3.526.3.1496)"
"Intervention, Performed: Substance Use Disorder Treatment" using "Substance Use Disorder Treatment (2.16.840.1.113883.3.464.1003.106.12.1005)"
"Medication, Order: Substance Use Disorder Long Acting Medication" using "Substance Use Disorder Long Acting Medication (2.16.840.1.113883.3.464.1003.1149)"
"Medication, Order: Substance Use Disorder Short Acting Medication" using "Substance Use Disorder Short Acting Medication (2.16.840.1.113883.3.464.1003.1150)"
"Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity (2.16.840.1.114222.4.11.837)"
"Patient Characteristic Payer: Payer Type" using "Payer Type (2.16.840.1.114222.4.11.3591)"
"Patient Characteristic Race: Race" using "Race (2.16.840.1.114222.4.11.836)"
"Patient Characteristic Sex: ONC Administrative Sex" using "ONC Administrative Sex (2.16.840.1.113762.1.4.1)"
"Procedure, Performed: Substance Use Disorder Long Acting Medication Administration" using "Substance Use Disorder Long Acting Medication Administration (2.16.840.1.113883.3.464.1003.1156)"
"Procedure, Performed: Substance Use Disorder Short Acting Medication Administration" using "Substance Use Disorder Short Acting Medication Administration (2.16.840.1.113883.3.464.1003.1157)"

Supplemental Data Elements

SDE Ethnicity

["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

["Patient Characteristic Payer": "Payer Type"]

SDE Race
- - ["Patient Characteristic Race": "Race"]

SDE Sex

["Patient Characteristic Sex": "ONC Administrative Sex"]

Risk Adjustment Variables

None

Measure Set

None